BAAM
UTHR icon

Baker Avenue Asset Management’s United Therapeutics UTHR Stock Holding History

Baker Avenue Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Buy
446
+5
+1% +$2.82K ﹤0.01% 731
2026
Q1 		$262K Buy
+441
New +$220K 0.01% 654
2023
Q4 		– Sell
-5
Closed -$1.13K – 1442
2023
Q3 		$1.13K Hold
5
– – ﹤0.01% 1247
2023
Q2 		$1.1K Sell
5
-4
-44% -$886 ﹤0.01% 1144
2023
Q1 		$2.02K Hold
9
– – ﹤0.01% 987
2022
Q4 		$2.5K Buy
+9
New +$2.27K ﹤0.01% 899

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Baker Avenue Asset Management's UTHR Position: Q2 2026 in Review

Baker Avenue Asset Management increased its United Therapeutics (UTHR) stake by 1.1% in Q2 2026, buying an estimated $2.82K and bringing the position to 446 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #731.

Baker Avenue Asset Management first reported a position in UTHR in Q4 2022 and has held it in 6 quarters since. The position peaked at $262K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Baker Avenue Asset Management held 446 shares of United Therapeutics worth $242K as of Q2 2026.
  • Baker Avenue Asset Management bought 5 United Therapeutics shares in Q2 2026, an estimated $2.82K.
  • United Therapeutics made up ﹤0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #731 holding.
  • Baker Avenue Asset Management first reported a position in United Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • Baker Avenue Asset Management's United Therapeutics position peaked at $262K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.